Peptide Biologix
Compound index
The atlas

Semax: Comprehensive Research Monograph

Synthetic ACTH(4–7)-Pro-Gly-Pro heptapeptide analogue (MEHFPGP; 813.93 g/mol) devoid of adrenal steroidogenic activity, studied for hippocampal BDNF/TrkB upregulation and cerebral ischemia neuroprotection.

Fine engraved study of an isolated feather with branching barbs
Plate 29Semax
Primary Heptapeptide Sequence H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (MEHFPGP · ACTH(4-7)-Pro-Gly-Pro)
Regulatory Status & Research Use Disclosure: Semax is not approved by the U.S. Food and Drug Administration for any human or veterinary diagnostic or therapeutic indication in the United States. On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, Semax is listed as nominated for Category 2, but withdrawn. All molecular, preclinical, clinical literature, and analytical information in this monograph is compiled strictly for laboratory research and educational reference.

Executive Summary

Semax is a synthetic heptapeptide derivative of adrenocorticotropic hormone (ACTH) fragment 4–10, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. The peptide demonstrates significant nootropic, neuroprotective, and neurorestorative properties through multiple mechanisms including modulation of brain-derived neurotrophic factor (BDNF), enhancement of dopaminergic and serotonergic neurotransmission, and regulation of oxidative stress and vascular-immune transcriptional pathways. This monograph provides a comprehensive analysis of Semax's molecular characterization, synthetic methodologies, mechanistic foundations, preclinical and clinical research outcomes, analytical methods for characterization, research applications, experimental dosing protocols, storage requirements, safety profile, and primary literature citations for scientific research purposes.

1. Molecular Characterization

1.1 Chemical Structure and Properties

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The peptide represents a modified fragment of ACTH(4-10) retaining the core ACTH(4-7) tetrapeptide (Met-Glu-His-Phe) coupled to a C-terminal Pro-Gly-Pro tripeptide sequence. This structural modification significantly enhances metabolic stability and bioavailability compared to the native ACTH(4-10) fragment (whose plasma half-life is under 2 minutes) while completely eliminating adrenal steroidogenic hormonal activity associated with full-length ACTH(1-39).

Table 1: Physicochemical Properties of Semax
Property Value
Molecular Formula C37H51N9O10S
Molecular Weight 813.92 g/mol
Sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
CAS Registry Number 80714-61-0
Isoelectric Point (pI) ~5.2
Solubility Soluble in water, PBS, and aqueous buffers
Appearance White to off-white lyophilized powder
Melting Point Decomposes before melting

1.2 Structural Biology and Conformation

The three-dimensional structure of Semax exhibits conformational flexibility in aqueous solution, a characteristic common to short linear neuropeptides. Nuclear magnetic resonance (NMR) spectroscopy studies have revealed that Semax adopts multiple conformational states in solution, with the N-terminal methionine and central histidine-phenylalanine residues playing critical roles in target recognition and biological activity. The Pro-Gly-Pro sequence at the C-terminus contributes to proteolytic resistance by creating steric and conformational hindrance against carboxypeptidases and endopeptidases.

Circular dichroism (CD) spectroscopy indicates that Semax displays minimal ordered α-helical secondary structure in aqueous buffer, consistent with an equilibrium between extended conformations and a polyproline II-like or β-turn tendency induced by the two proline residues at positions 5 and 7. Upon interaction with membrane mimetic environments or receptor binding domains, the His3-Phe4 aromatic core adopts a defined orientation that facilitates biological signaling.

1.3 Structure-Activity Relationships

Extensive structure-activity relationship (SAR) studies conducted by Ashmarin, Myasoedov, and colleagues identified critical residues for Semax's biological activity. The N-terminal Met-Glu-His-Phe sequence derived from ACTH(4-7) represents the minimal pharmacophore required for nootropic effects and neurotrophic factor modulation. The C-terminal Pro-Gly-Pro tripeptide (an endogenous glyproline motif) significantly enhances resistance to serum and brain peptidases and generates bioactive proteolytic fragments (including hexapeptide Glu-His-Phe-Pro-Gly-Pro and tripeptide Pro-Gly-Pro) that contribute to the prolonged duration of behavioral and transcriptional action (exceeding 20–24 hours after a single administration).

2. Synthesis and Manufacturing

2.1 Solid-Phase Peptide Synthesis

Semax is synthesized using standard solid-phase peptide synthesis (SPPS) methodologies, predominantly employing Fmoc (9-fluorenylmethoxycarbonyl) chemistry. The synthesis proceeds stepwise from the C-terminus (Fmoc-Pro-Wang or 2-chlorotrityl chloride resin) to the N-terminus.

The synthetic protocol involves sequential cycles of:

  • Deprotection: Removal of Fmoc protecting groups using 20% piperidine in dimethylformamide (DMF)
  • Activation: Coupling of protected amino acids—Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Phe-OH, Fmoc-His(Trt)-OH, Fmoc-Glu(OtBu)-OH, and Fmoc-Met-OH—using coupling reagents such as HBTU, HATU, or DIC/HOBt
  • Coupling: Formation of peptide bonds between successive amino acids in the presence of base (typically N,N-diisopropylethylamine, DIPEA)
  • Capping: Acetylation of unreacted amino groups to prevent deletion sequences

2.2 Cleavage and Deprotection

Following complete assembly of the heptapeptide sequence, the peptide is cleaved from the solid support and side-chain protecting groups (Trt on His3, OtBu on Glu2) are removed using a cleavage cocktail consisting of trifluoroacetic acid (TFA) 95%, triisopropylsilane (TIS) 2.5%, and water 2.5%. The cleavage reaction is performed for 2–3 hours at room temperature under nitrogen. The crude peptide is precipitated using cold diethyl ether or methyl tert-butyl ether (MTBE), collected by centrifugation, and washed multiple times.

2.3 Purification and Quality Control

Crude Semax is purified using reversed-phase high-performance liquid chromatography (RP-HPLC) on preparative C18 columns employing a linear gradient of water and acetonitrile containing 0.1% TFA, followed by counter-ion exchange to the acetate salt. Purified fractions are analyzed by analytical RP-HPLC and mass spectrometry to confirm identity and purity:

  • Amino acid analysis to confirm 1:1:1:1:2:1 molar composition
  • Mass spectrometry (ESI-MS or MALDI-TOF MS) to verify molecular weight (813.93 g/mol)
  • Analytical HPLC to assess chromatographic purity and verify absence of Met(O)1 sulfoxide impurity
  • Peptide content determination by quantitative amino acid analysis or elemental nitrogen
  • Water content by Karl Fischer titration
  • Counter-ion analysis (acetate / residual TFA content)
Table 2: Typical Specifications for Research-Grade Semax
Parameter Specification
Purity (RP-HPLC) ≥95% (typically ≥98.0%)
Peptide Content ≥80% (dry basis)
Water Content (Karl Fischer) ≤10%
Residual TFA Content ≤2%
Mass Accuracy (ESI-MS) ±0.5 Da from theoretical MW
Endotoxin Level (USP <85>) <0.5 EU/mg (for in vivo research grade)

3. Mechanism of Action

3.1 Neurotrophic Factor Modulation (BDNF / TrkB Axis)

Semax exerts rapid and pronounced effects on the expression and signaling of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Foundational studies by Dolotov et al. (2006) demonstrated that single intranasal administration of Semax in rats increases BDNF mRNA levels and BDNF protein levels by up to 2-fold in the hippocampus, alongside upregulation of TrkB receptor mRNA within 3 to 24 hours. This transcriptional upregulation is mediated through activation of the cAMP response element-binding protein (CREB) pathway.

Increased BDNF bioavailability activates high-affinity tropomyosin receptor kinase B (TrkB) receptors on hippocampal and cortical neurons, initiating downstream MAPK/ERK, PI3K/Akt, and PLCγ signaling cascades. These pathways promote neuronal survival, synapsin-1 phosphorylation, dendritic spine remodeling, and hippocampal CA1 long-term potentiation (LTP).

3.2 Monoaminergic Neurotransmission

Semax modulates multiple monoaminergic neurotransmitter systems, with particularly significant effects on dopaminergic and serotonergic pathways (Eremin et al., 2005; Levitskaya et al., 2008). Microdialysis studies in rodents have revealed that Semax administration increases extracellular dopamine concentrations and homovanillic acid (HVA) in the striatum and nucleus accumbens, brain regions involved in motivation, reward processing, and motor control. This effect is mediated by enhanced dopamine synthesis through upregulation of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis, and potentiation of stimulus-evoked dopaminergic release rather than direct reuptake inhibition. In the serotonergic system, Semax increases serotonin turnover (5-HIAA) and enhances serotonergic neurotransmission in the hippocampus, hypothalamus, and prefrontal cortex, modulating 5-HT1A and 5-HT2A receptor signaling alongside locus coeruleus noradrenergic activity.

3.3 Melanocortin Receptor Interactions

As a derivative of the ACTH(4-10) sequence containing the conserved His-Phe core, Semax interacts with central melanocortin receptors (particularly MC4R and MC3R) as well as high-affinity non-classical ACTH(4-10) binding sites in basal forebrain and hippocampal membranes, while exhibiting zero agonist activity at peripheral adrenal MC2R receptors (explaining the complete absence of corticosterone/cortisol stimulation).

3.4 Antioxidant, Anti-inflammatory, and Transcriptomic Effects in Ischemia

Genome-wide transcriptional profiling by Medvedeva et al. (2014) in rat models of transient middle cerebral artery occlusion (tMCAO) demonstrated that Semax alters the expression of more than 90 genes in the ischemic cortex within 3 to 24 hours post-reperfusion. Specifically, Semax suppresses ischemia-induced pro-inflammatory cytokine cascades (downregulating Il1b, Il6, Tnfa, and matrix metalloproteinase-9) while upregulating genes governing vascular remodeling, angiogenesis, and antigen presentation/immunoglobulin heavy-chain neurovascular repair pathways.

3.5 Neuroprotective Mechanisms

Semax attenuates glutamate-induced excitotoxicity by blunting NMDA-receptor-mediated intracellular Ca2+ overload in primary cortical neurons, upregulates anti-apoptotic Bcl-2 family proteins while suppressing caspase-3 cleavage, and preserves mitochondrial membrane potential under oxidative stress.

4. Preclinical Research

4.1 Cognitive Enhancement Studies

Extensive preclinical research has demonstrated Semax's cognitive-enhancing properties across multiple rodent behavioral paradigms. In Morris water maze and passive avoidance studies, rats treated with Semax exhibit significantly accelerated spatial learning acquisition and enhanced 24-hour memory retention compared to vehicle controls. These behavioral improvements correlate directly with hippocampal CA1 BDNF protein levels and TrkB phosphorylation.

4.2 Neuroprotection in Stroke Models

Semax has been extensively investigated in preclinical models of focal and global cerebral ischemia (Gusev et al., 2005; Stavchansky et al., 2011; Medvedeva et al., 2014). In rat middle cerebral artery occlusion (MCAO) and photothrombotic prefrontal cortex stroke models, intranasal or intraperitoneal administration of Semax reduces cortical infarct volume by 30–50%, preserves neuronal density in the ischemic penumbra, stimulates proliferative activity of neuroglial progenitor cells in the subgranular and subventricular zones, and accelerates sensorimotor recovery.

4.3 Neurodegenerative Disease Models

Research in animal models of neurodegenerative diseases has revealed notable neuroprotective effects of Semax. In models of Parkinsonian dopaminergic injury induced by 6-hydroxydopamine (6-OHDA) or MPTP neurotoxins (Shadrina et al., 2007), Semax protects nigrostriatal tyrosine hydroxylase-positive (TH+) neurons from degeneration, preserves striatal dopamine content, and attenuates rotational motor asymmetry. In amyloid-beta toxicity models, Semax complexes copper(II) ions via its His3 imidazole ring, inhibiting Cu2+-catalyzed amyloid-beta fibrillogenesis and reactive oxygen species generation.

4.4 Attention and Stress Adaptation Studies

In five-choice serial reaction time tasks (5-CSRTT) and chronic unpredictable stress paradigms, Semax improves sustained attention accuracy, prevents stress-induced hippocampal BDNF suppression, and normalizes stress-elevated corticosterone levels without inducing sedation or locomotor suppression.

5. Clinical Studies and Human Research

5.1 Cerebrovascular Disorders and Stroke

Clinical trials conducted in Russia have investigated Semax in patients with acute ischemic stroke and chronic cerebrovascular insufficiency (Gusev et al., 2005). A randomized, placebo-controlled trial involving 120 patients with acute ischemic stroke treated within 6–12 hours of symptom onset demonstrated significant improvements in neurological recovery as measured by the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) at 30 and 90 days post-stroke compared to standard care alone, accompanied by reduced lesion volume expansion on MRI and elevated plasma BDNF concentrations. In patients with chronic cerebrovascular insufficiency and vascular cognitive impairment (N=85), controlled clinical studies reported improved cognitive performance on neuropsychological assessments of attention, memory, and executive function, with benefits maintained for several weeks after treatment cessation.

5.2 Cognitive Function in Healthy Volunteers

A double-blind, placebo-controlled crossover study in 30 healthy adults (Kaplan et al., 1996) demonstrated that acute intranasal Semax administration improved performance on sustained attention tasks, working memory tests, and psychomotor speed assessments compared to placebo, accompanied by increased EEG alpha/beta coherence across frontoparietal leads without stimulant-like cardiovascular effects.

5.3 Optic Nerve Pathology

Clinical trials in 65 patients with optic nerve atrophy, glaucomatous optic neuropathy, and ischemic optic neuropathy reported improvements in visual field parameters, contrast sensitivity, and visual evoked potential (VEP) latencies.

5.4 Attention Deficit Disorders

Clinical observations have also examined Semax in attention deficit hyperactivity disorder (ADHD). A pilot study in 45 children with ADHD reported that intranasal Semax improved attention span, reduced impulsivity, and enhanced academic performance as rated by parents and teachers using standardized ADHD rating scales, with a side-effect profile lacking the appetite suppression and sleep disturbances associated with conventional psychostimulants.

5.5 Immune Modulation

Clinical research in patients with immunodeficiency states has shown that Semax normalizes immune parameters including lymphocyte populations, natural killer (NK) cell activity, and cytokine production without causing excessive immune activation or inflammatory responses.

Table 3: Summary of Published Clinical Studies with Semax
Indication Study Design Sample Size Primary Reported Outcome
Acute Ischemic Stroke Randomized, placebo-controlled trial 120 patients Improved NIHSS and mRS scores at 30 and 90 days
Cerebrovascular Insufficiency Open-label / controlled clinical study 85 patients Enhanced neuropsychological cognitive performance
Cognitive Enhancement Double-blind, placebo-controlled crossover 30 healthy adults Improved sustained attention and working memory
Optic Neuropathy Randomized clinical trial 65 patients Improved visual field parameters and VEP latency
ADHD Pilot clinical study 45 children Reduced standardized ADHD rating scale symptoms

Regulatory Note: Although intranasal Semax formulations have been registered for clinical use in the Russian Federation since the 1990s, Semax has not undergone multi-center Phase III registration trials under U.S. FDA or EMA regulatory oversight and is not approved for clinical use in the United States or European Union.

6. Analytical Methods and Characterization

6.1 High-Performance Liquid Chromatography (RP-HPLC)

Reversed-phase HPLC represents the primary analytical method for Semax purity assessment and quantification. Standard analytical protocols employ a C18 column (4.6 × 150 mm or 4.6 × 250 mm, 5 μm particle size) with gradient elution using aqueous TFA (0.1% in water) and acetonitrile containing 0.1% TFA (typically 5–10% to 50–60% acetonitrile over 20–30 minutes at 1.0 mL/min) and UV detection at 214–220 nm. The HPLC method must demonstrate adequate resolution between intact Semax and potential impurities including deletion sequences (des-Met and des-Pro variants), oxidized methionine variants ([Met(O)1]-Semax), and deamidation products.

6.2 Mass Spectrometry

Electrospray ionization mass spectrometry (ESI-MS) in positive-ion mode generates multiply charged ions with the doubly protonated species [M+2H]2+ at m/z 407.5 and the triply protonated species [M+3H]3+ at m/z 272.0, while MALDI-TOF MS generates predominantly singly protonated molecular ions [M+H]+ at m/z 814.4. High-resolution MS/MS collision-induced dissociation (CID) confirms the MEHFPGP sequence through b-ion and y-ion series identification.

6.3 Amino Acid Analysis and Peptide Content

Quantitative amino acid analysis (AAA) following 6 N HCl hydrolysis (110 °C for 20–24 hours) confirms the theoretical 1:1:1:1:2:1 molar ratio of Met:Glu:His:Phe:Pro:Gly and establishes net peptide content (typically 70–85% on an as-is basis, with the remainder consisting of water and counter-ions).

6.4 Independent Third-Party CoA Verification

7. Research Applications

  • Neurotrophin & Synaptic Plasticity Research: Investigating rapid CREB-dependent Bdnf exon-specific transcription, TrkB receptor phosphorylation, and hippocampal CA1 long-term potentiation (LTP).
  • Experimental Cerebral Ischemia (MCAO): Studying neurovascular unit transcriptomics, microglial M1/M2 polarization, and penumbral neuroprotection in focal stroke models.
  • Monoaminergic & Nigrostriatal Pharmacology: Examining tyrosine hydroxylase regulation, striatal dopamine/serotonin turnover, and neuroprotection against MPTP or 6-OHDA toxicity.
  • Metal-Ion & Amyloid Biophysics: Studying Cu2+ coordination by the N-terminal Met-Glu-His motif and inhibition of metal-catalyzed amyloid-beta aggregation.

8. Dosing Protocols for Research

8.1 Preclinical Research Dosing

In rodent research models, Semax is administered via intranasal, intraperitoneal, or subcutaneous routes. Intranasal administration is frequently selected in neuropharmacology studies due to direct olfactory and trigeminal perineural transport into the cranial cavity.

Table 4: Published Preclinical Research Regimens Literature summary of published study doses, routes, and schedules.
Experimental Model Species / System Route Published Dose Range Schedule
Cognitive Enhancement Rat Intranasal 100 – 300 μg/kg Once daily, 7–14 days
Acute Stroke (MCAO) Rat Intranasal / IP 500 – 1,000 μg/kg Single dose or daily × 3–5 days
Neurodegenerative Models Mouse Intranasal 200 – 400 μg/kg Daily, 14–28 days
In Vitro Culture Cell culture Medium addition 1 – 100 μM Varies by experimental protocol

8.2 Solution Preparation for Research

For in vivo preclinical research, lyophilized Semax is dissolved in sterile 0.9% sodium chloride, phosphate-buffered saline (PBS, pH 7.4), or sterile water at 1–5 mg/mL. For cell culture studies, stock solutions (1–10 mM) are prepared in sterile water or PBS and stored as single-use frozen aliquots at −20 °C or −80 °C.

9. Storage and Stability

9.1 Lyophilized Peptide Storage

Lyophilized Semax demonstrates optimal stability when stored desiccated at −20 °C or −80 °C in sealed containers protected from moisture and light. Under these conditions, the peptide maintains >95% purity for at least 24 months. Storage at 2–8 °C is acceptable for short-term storage (up to 6 months).

9.2 Reconstituted Solution Stability and Oxidation Prevention

In sterile saline or PBS (pH 6.5–7.5) stored at 2–8 °C away from light, reconstituted Semax solutions retain acceptable stability (>90% intact peptide) for 7–14 days. Because the N-terminal methionine thioether group (−S−CH3) is susceptible to dissolved-oxygen and trace-metal-catalyzed oxidation to methionine sulfoxide, long-term storage of reconstituted stocks requires aliquoting into single-use vials and freezing at −20 °C or −80 °C (3–6 months) without repeated freeze-thaw cycles.

10. Safety Profile and Considerations

10.1 Preclinical Safety and Toxicology

Extensive preclinical toxicology studies in mice and rats established LD50 values exceeding 10,000 times the effective pharmacological dose, with acute doses up to 100 mg/kg showing no signs of toxicity, behavioral abnormalities, or mortality. Chronic 6-month repeat-dose toxicity and reproductive toxicology studies in rodents revealed no organ toxicity, hepatotoxicity, nephrotoxicity, neurotoxicity, or teratogenicity.

10.2 Clinical Tolerability and Evidence Limitations

In published Russian clinical studies, intranasal Semax was well tolerated, with transient mild nasal mucosal irritation, mild headache, or occasional dizziness resolving without intervention. Semax does not alter arterial blood pressure, heart rate, ECG intervals, or serum cortisol concentrations, and exhibits no sedative, psychostimulant-addictive, or withdrawal liabilities. However, long-term safety data beyond 3–6 months of continuous use remains limited, and the potential for tolerance with extended chronic administration has not been systematically evaluated in large multicenter cohorts.

11. Literature Review and Key Publications

  1. Ashmarin IP, Nezavibat'ko VN, Myasoedov NF, Kamenskii AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AIA, Koshelev VB, Riasina TV. The nootropic adrenocorticotropin analog Semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-430. PMID: 9234274
  2. Gusev EI, Skvortsova VI, Chukanova EI, Platova AL, Nesterova IV, Kovalenko AV. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40. PMID: 15768548
  3. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. doi: 10.1186/1471-2164-15-228. PMID: 24666810
  4. Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Antiparkinsonian action of semax. Mol Biol (Mosk). 2007;41(5):899-907. PMID: 18163254
  5. Levitskaya NG, Sebentsova EA, Glazova NYu, Manchenko DM, Andreeva LA, Kamenskii AA, Myasoedov NF, Khomutov AE. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem J. 2008;2(2):111-116. doi: 10.1134/S1819712408020062
  6. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. doi: 10.1016/j.brainres.2006.07.108. PMID: 16962082
  7. Stavchansky VV, Yuzhakov VV, Botsina AY, Skvortsova VI, Bondurko LN, Tsyganova MG, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. J Mol Neurosci. 2011;45(2):177-185. doi: 10.1007/s12031-010-9421-2. PMID: 20680704
  8. Kaplan AY, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. Synthetic acth analogue Semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115-123.
  9. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. doi: 10.1007/s11064-005-8826-8. PMID: 16362768
  10. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545-1564. doi: 10.1098/rstb.2006.1894. PMID: 16939974

12. Research Considerations and Future Directions

Despite extensive preclinical and Russian clinical literature, several mechanistic and translational questions remain active areas of research: (1) definitive characterization of the primary high-affinity membrane receptor complex mediating rapid hippocampal CREB/BDNF induction; (2) quantitative LC-MS/MS pharmacokinetics of intact Semax versus its bioactive proteolytic cleavage products (such as Glu-His-Phe-Pro-Gly-Pro and Pro-Gly-Pro) in cerebrospinal fluid following intranasal delivery; (3) evaluation of long-term safety and potential tolerance beyond 3–6 months of continuous administration; and (4) comparative transcriptomic studies alongside structurally related neuropeptides including Selank, Cerebrolysin, Dihexa, Noopept, and P21.

13. Conclusion

Semax represents a well-characterized synthetic heptapeptide with significant nootropic, neuroprotective, and neurorestorative properties supported by extensive preclinical and clinical research. The peptide's mechanisms of action involve modulation of neurotrophic factors (particularly BDNF), enhancement of monoaminergic neurotransmission, antioxidant and anti-inflammatory effects, and activation of endogenous neuroprotective pathways. Future research addressing current knowledge gaps and exploring novel experimental applications and formulations is expected to further expand the utility of Semax in neuroscience research.